Merck & Co., Inc. Release: New Data Show Significant Reductions In Both Post-Meal And Fasting Blood Sugar Levels With Sitagliptin Phosphate Plus Metformin As Initial Therapy In Patients With Type 2 Diabetes
CAPE TOWN, South Africa--(BUSINESS WIRE)--Initial treatment with sitagliptin phosphate 50 mg twice daily in combination with metformin 1,000 mg twice daily provided substantial reductions of post prandial, or post-meal, glucose (PPG) levels and fasting plasma glucose (FPG) levels in patients with type 2 diabetes, according to new data presented for the first time today at the 19th World Diabetes Congress in Cape Town. Patients with a mean baseline 2-hour PPG of 287 mg/dL (n=152) achieved reductions of 117 mg/dL, and patients with a mean baseline FPG of 197 mg/dL (n=180) achieved reductions of 70 mg/dL, compared to placebo (primary analysis of all patients treated, p<0.001).